CN101166514A - 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法 - Google Patents

用于提供持续释放的纳米粒组合物的可注射储库制剂及方法 Download PDF

Info

Publication number
CN101166514A
CN101166514A CNA2006800144209A CN200680014420A CN101166514A CN 101166514 A CN101166514 A CN 101166514A CN A2006800144209 A CNA2006800144209 A CN A2006800144209A CN 200680014420 A CN200680014420 A CN 200680014420A CN 101166514 A CN101166514 A CN 101166514A
Authority
CN
China
Prior art keywords
preparation
ziprasidone
weight
another embodiment
stabilizing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800144209A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·沙
P·S·沙
D·R·瓦格纳
P·维斯尼基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN101166514A publication Critical patent/CN101166514A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2006800144209A 2005-04-13 2006-04-10 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法 Pending CN101166514A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67112405P 2005-04-13 2005-04-13
US60/671,124 2005-04-13

Publications (1)

Publication Number Publication Date
CN101166514A true CN101166514A (zh) 2008-04-23

Family

ID=36602931

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800144209A Pending CN101166514A (zh) 2005-04-13 2006-04-10 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法

Country Status (14)

Country Link
US (1) US20080193542A1 (enExample)
EP (1) EP1874268A1 (enExample)
JP (1) JP2008538751A (enExample)
KR (1) KR20070119678A (enExample)
CN (1) CN101166514A (enExample)
AU (2) AU2006233345A1 (enExample)
BR (1) BRPI0609299A2 (enExample)
CA (1) CA2605153A1 (enExample)
IL (1) IL186131A0 (enExample)
MX (1) MX2007012103A (enExample)
NZ (1) NZ561950A (enExample)
RU (1) RU2407529C2 (enExample)
WO (1) WO2006109183A1 (enExample)
ZA (1) ZA200708188B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104814926A (zh) * 2015-04-08 2015-08-05 中国药科大学 一种鲁拉西酮纳米混悬剂及其制备方法
CN109998991A (zh) * 2019-04-28 2019-07-12 中国药科大学 一种盐酸鲁拉西酮长效肌肉注射纳米混悬液及其制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2001032148A1 (en) 1999-10-29 2001-05-10 Euro-Celtique, S.A. Controlled release hydrocodone formulations
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
EP1901722A4 (en) * 2005-06-20 2011-06-15 Elan Pharma Int Ltd NANOTEHOUS COMPOSITIONS WITH CONTROLLED RELEASE FROM ARYL-HETEROCYCLIC COMPOUNDS
MX2007016151A (es) * 2005-06-20 2008-03-06 Elan Pharma Int Ltd Composiciones de liberacion controlada y en forma de nano-particulas que comprenden compuestos aril-heterociclicos.
AU2008274185B2 (en) * 2007-07-12 2014-07-03 Janssen Sciences Ireland Uc Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
EP2629775A4 (en) 2010-10-18 2014-06-11 Dainippon Sumitomo Pharma Co INJECTABLE FORMULATION WITH DELAYED RELEASE
CA2832410C (en) 2011-04-15 2019-07-23 Janssen Pharmaceutica Nv Freeze dried drug nanosuspensions
US20170079985A1 (en) * 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
KR102847306B1 (ko) * 2021-08-13 2025-08-18 단국대학교 천안캠퍼스 산학협력단 결정형 몬테루카스트를 포함하는 지속성 현탁 주사제 및 이의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
MXPA05002561A (es) * 2002-10-25 2005-05-05 Pfizer Prod Inc Nuevas formulaciones de liberacion prolongada inyectables.
AU2003300814A1 (en) * 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104814926A (zh) * 2015-04-08 2015-08-05 中国药科大学 一种鲁拉西酮纳米混悬剂及其制备方法
CN109998991A (zh) * 2019-04-28 2019-07-12 中国药科大学 一种盐酸鲁拉西酮长效肌肉注射纳米混悬液及其制备方法

Also Published As

Publication number Publication date
AU2006233345A1 (en) 2006-10-19
CA2605153A1 (en) 2006-10-19
RU2407529C2 (ru) 2010-12-27
US20080193542A1 (en) 2008-08-14
AU2010201801A1 (en) 2010-05-27
KR20070119678A (ko) 2007-12-20
BRPI0609299A2 (pt) 2010-03-23
WO2006109183A1 (en) 2006-10-19
EP1874268A1 (en) 2008-01-09
NZ561950A (en) 2010-09-30
JP2008538751A (ja) 2008-11-06
MX2007012103A (es) 2007-11-20
IL186131A0 (en) 2008-01-20
RU2007137846A (ru) 2009-06-20
ZA200708188B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
US20080305161A1 (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
AU2010201801A1 (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US20080166411A1 (en) Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
TWI558422B (zh) 減少奈米顆粒活性劑組成物中薄片狀聚集之技術
AU719085B2 (en) Processes of preparing or stabilising microparticles
CN101801342B (zh) 制造阿立哌唑悬浮液和冻干制剂的方法
Cerdeira et al. Formulation and drying of miconazole and itraconazole nanosuspensions
JPH10508614A (ja) 飽和溶解度と溶解速度を増大させた薬剤投与用ナノ懸濁液
EP1874267A1 (en) Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
JP2006504733A (ja) 薬学的用途のための固体粒状抗真菌性組成物
CN1761454A (zh) 小颗粒的制备方法
CN101106972A (zh) 注射用纳米微粒奥氮平制剂
WO2010138661A1 (en) Nanoparticulate anticancer compositions and methods for making the same
KR20170070025A (ko) 아비라테론 아세테이트 제제 및 사용 방법
DK1731138T3 (en) Fine dispersion of sparingly soluble drug and the process for preparing the
CA2913611C (en) Nanoparticulate compositions and formulations of piperazine compounds
WO2015068105A1 (en) An improved process for manufacturing sterile ophthalmic pharmaceutical suspensions
HK1117740A (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CN112236141A (zh) 包含德拉马尼的组合物
US20070224282A1 (en) Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same
HK40009384A (en) Injectable pharmaceutical composition containing meloxicam, and preparation method therefor
MXPA99001691A (es) Composiciones que comprenden microparticulas de sustancias insolubles en agua, y metodo para su preparacion

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1117740

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20080423

C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1117740

Country of ref document: HK